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Bovine Mastitis Pathogens
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Abstract
Economic losses due to bovine mastitis is estimated to be $2 billion in the United 
States alone. Antimicrobials are used extensively in dairy farms for prevention and 
treatment of mastitis and other diseases of dairy cattle. The use of antimicrobials 
for treatment and prevention of diseases of dairy cattle needs to be prudent to slow 
down the development, persistence, and spread of antimicrobial-resistant bacteria 
from dairy farms to humans, animals, and farm environments. Because of public 
health and food safety concerns regarding antimicrobial resis tance and antimicro-
bial residues in meat and milk, alternative approaches for disease control required 
These include vaccines, improvements in housing, management practices that 
reduce the likelihood and effect of infectious diseases, management systems and 
feed formulation, studies to gain a better understanding of animal behavior, and the 
development of more probiotics and competitive exclusion products are required. 
Monitoring antimicrobial resistance patterns of bacterial isolates from cases of mas-
titis and dairy farm environments is important for treatment decisions and proper 
design of antimicrobial-resistance mitigation measures. It also helps to determine 
emergence, persistence, and potential risk of the spread of antimicrobial-resistant 
bacteria and resistome from these reservoirs in dairy farms to humans, animals, and 
farm environments.
Keywords: antimicrobial resistance, vaccines against mastitis, bovine mastitis, 
bacterial mastitis pathogens, bacterial pathogens, current status
1. Introduction
1.1 Antibiotic use in dairy farms and antimicrobial resistance
Economic losses due to bovine mastitis is estimated to be $2 billion in the United 
States alone [1]. Most studies showed that there is no widespread, emerging resis-
tance among mastitis pathogens [2–4] in dairy farms. Some studies showed that the 
antimicrobial resistance of mastitis pathogens varies with dairy farms and bacterial 
species within and among dairy farms [4–9]. However, antimicrobial resistance 
patterns of human pathogenic bacteria and their resistome in dairy farms might be 
of significant concern.
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On average, starting from calving (giving birth) dairy cow is milked (in lacta-
tion) for about 300 days and then dried off (stop milking) for about 60 days before 
they calve again. Under the ideal dairy farming condition, a dairy cow should 
become pregnant within 60 days of calving, and the lactation cycle continues 
(Figure 1). The goal of a dry period is to give them a break from milking so that 
milk-producing cells regenerate, multiply, and ready for the next cycle of lactation. 
The incidence of intramammary infection (IMI) by bacteria is high during the 
early dry period and transition periods [10]. In general, for a dairy cow, a transition 
period, also known as the periparturient period, is a time range from three weeks 
before parturition (non-milking time) until three weeks after calving (milking 
time). It is a transition time from non-milking to milking.
Dairy cows are susceptible to mastitis during early non-lactating (dry period) 
and transition periods [11, 12], especially new infection with environmental patho-
gens (Streptococcus spp. and coliform) are highest during the first two weeks after 
drying off and last two weeks before calving [13] compared to contagious mastitis 
pathogens such as S. aureus [14]. The incidence of intramammary infection is high 
during the early dry period because of an absence of hygienic milking practices 
such as pre-milking teat washing and drying [15], pre- and post-milking teat dip-
ping in antiseptic solutions [16, 17], that are known to reduce teat end colonization 
by bacteria and infection. An udder infected during the early dry period usually 
manifests clinical mastitis during the transition period [18] because of increased 
production of parturition inducing immunosuppressive hormones [19], negative 
energy balance [12], and physical stress during calving [20].
Cows are naturally protected against intramammary infections during the dry 
period by physical barriers such as the closure of teat opening by smooth muscle 
(teat sphincter) and the formation of a keratin plug, fibrous structural proteins 
(scleroproteins) [21, 22], in the teat canal produced by teat canal epithelium [23]. 
Keratin contains a high concentration of fatty acids, such as lauric, myristic, and 
palmitoleic acids, which are associated with reduced susceptibility to infection and 
stearic, linoleic, and oleic acids that are associated with increased susceptibility to 
infection. Keratin also contains antibacterial proteins that can damage the cell wall 
of some bacteria by disrupting the osmoregulatory mechanism [23]. However, the 
Figure 1. 
Antimicrobials usage patterns during the lactation cycle. DIM: Days in milk, yellow star: Peak lactation at 60 
DIM, green bars: Energy demand that requires the mobilization of body energy reserve at the expense of losing 
bodyweight, red bumps showed increased usage of antimicrobials.
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time of teat canal closure varies among cows. Some studies showed that 50% of 
teat canals were classified as closed by seven days after drying off, 45% closed over 
the following 50–60 days after drying off, and 5% had not closed by 90 days after 
dry off [24]. Teats that do not form a plug-like keratin seal are believed to be most 
susceptible to infection. Infusion of long-acting antimicrobials into the udder at 
drying-off (dry cow therapy) has been the major management tool for the preven-
tion of IMI during the dry period, as well as to clear IMI established during the 
previous lactation [24].
In the United States and many other countries at the end of lactation (at drying 
off), all cows regardless of their health status, are given an intramammary infu-
sion of long-acting antimicrobials (blanket dry cow therapy) to prevent IMI by 
bacteria during the dry period [3, 25]. Because of increased concern on the use of 
blanket dry cow therapy for its role in driving antimicrobial resistance, selective 
dry cow therapy (intramammary infusion of antimicrobials into only quarters that 
have tendency or risk of infection) has been under investigation [26, 27]. Some 
recent studies showed that the use of bacteriological culture-based selective dry 
cow therapy at drying-off did not negatively affect cow health and performance 
during early lactation [26, 27]. In general, dairy farms are one of the largest users 
of antimicrobials including medically important antimicrobials [28]. Some of the 
antimicrobials used in dairy farms include beta-lactams (penicillins, Ampicillin, 
oxacillin, penicillin-novobiocin), extended-spectrum beta-lactams (third-genera-
tion cephalosporins, e.g., ceftiofur), aminoglycosides (streptomycin), macrolides 
(erythromycin), lincosamide (pirlimycin), tetracycline, sulfonamides, and fluo-
roquinolones [28–30]. Antimicrobials are also heavily used in dairy farms for the 
treatment of cases of mastitis [3, 25, 31] and other diseases of dairy cows such as 
metritis, retained placenta, lameness, diarrhea, pneumonia, [32–36] and neonatal 
calf diarrhea [37]. Over 90% of dairy farms in the US infuse all udder quarters of 
all cows with antimicrobial regardless of their health status [7, 25, 38]. According 
to dairy study in 2007 that was conducted in 17 major dairy states in the United 
States, 85.4% of farms use antibiotics for mastitis, 58.6% for lameness, 55.8% for 
diseases of the respiratory system, 52.9% for diseases of reproductive system, 25% 
for diarrhea or gastrointestinal infections and 6.9% for all other health problems 
[3, 25]. Cephalosporins were the most widely used antibiotics for the treatment of 
mastitis, followed by lincosamides and non-cephalosporin beta-lactam antibiotics 
[3, 25]. The two most commonly used antibiotics for dry cow therapy are Penicillin 
G/dihydrostreptomycin and cephalosporins [3, 25]. Antimicrobials were adminis-
tered for the prevention and treatment of mastitis and other diseases of dairy cattle 
mainly through intramammary infusion and intramuscular route (USDA APHIS, 
2009a). Antimicrobials infused into the mammary glands can be excreted to the 
environment through leakage of milk from the antimicrobial-treated udder or 
absorbed into the body and enter the blood circulation and biotransformed in the 
liver or kidney and excreted from the body through urine or feces into the environ-
ments [39–42]. Similarly, antimicrobials administered through parenteral routes 
for the treatment of acute or peracute mastitis or other diseases of dairy cows will 
enter the blood circulation and biotransformed in the liver or kidney and excreted 
from the body through urine or feces into the environments [39–42]. Therefore, 
both parenteral and intramammary administration of antibiotics has a significant 
impact on other commensals or opportunistic bacteria in the gastrointestinal tract 
of dairy cows and farm environments.
In addition to the use of antimicrobials for the prevention and treatment of 
mastitis and other diseases of dairy cattle, some farms also feed raw waste milk 
or pasteurized waste milk from antibiotic-treated cows to dairy calves. Feeding of 
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raw waste milk or pasteurized waste milk from antibiotic-treated cows to calves 
increases pressure on gut microbes such as E. coli to became antimicrobial-resistant 
[43–45]. Aust et al. [43] showed that the proportion of antimicrobial-resistant E. 
coli, especially cephalosporin-resistant E. coli isolates, was significantly higher in 
calves fed waste milk or pasteurized waste milk from antimicrobial treated cows 
than calves fed bulk tank milk from non-antibiotic treated cows. However, pasteur-
ized waste milk from cows not treated with antimicrobials is acceptable to be feed 
to young calves [43] but it is not known if pasteurization prevents the transfer 
of antimicrobial-resistant genes to microbes in the calve’s gut. Some studies also 
showed that feeding pasteurized waste milk from antimicrobial treated cows to 
calves increased the presence of phenotypic resistance to ampicillin, cephalothin, 
ceftiofur, and florfenicol in fecal E. coli compared with milk replacer-fed calves 
[45]. However, the presence of resistance to sulfonamides, tetracyclines, and 
aminoglycosides was common in dairy calves regardless of the source of milk, 
suggesting other driving factors for resistance development [45]. It has been sug-
gested that antimicrobial residues present in waste milk have a non-specific effect 
at a lower taxonomical level [44]. Collectively, these non-prudent antimicrobials 
usage practices in dairy farms expose a large number of animals in dairy farms to 
antimicrobials and also increases the use of antimicrobials in dairy farms, which in 
turn creates intense pressure on microbes in animals’ body especially commensal 
and opportunistic microbes in the gastrointestinal tract and farm environments. 
Some of these commensal bacteria in the animal body are serious human pathogens 
(e.g., E. coli 0157:H7). Staphylococcus aureus is one of the pathogens with a known 
ability to develop antimicrobial resistance and established S. aureus infections are 
persistent and difficult to clear. The failure to control these infections leads to the 
presence of reservoirs in the dairy herd, which ultimately leads to the spread of the 
infection and the culling of the chronically infected cows [46, 47].
Monitoring antimicrobial resistance patterns of bacterial isolates from cases 
of mastitis is important for treatment decisions and proper design of mitigation 
measures. It also helps to determine emergence, persistence, and potential risk of 
the spread of antimicrobial-resistant bacteria and resistome to human, animal, 
and environment [48, 49]. The prudent use of antimicrobials in dairy farms 
reduce emergence, persistence, and spread of antimicrobial-resistant bacteria and 
resistome from dairy farms to human, animal, and environment.
1.2 Transmission of antimicrobial-resistant bacteria from dairy farms to human
Most studies showed that there is no widespread, emerging resistance among 
mastitis pathogens [2–4] in dairy farms. However, dairy farms may serve as a source 
of antimicrobial-resistant human pathogenic bacteria. Extensive use of third-
generation cephalosporins (3GCs) in dairy cattle for the prevention and treatment 
of mastitis [3, 25, 28] and other diseases of dairy cattle [31, 32] can result in the 
carriage of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL 
Ent) [50, 51]. Third- and fourth-generation cephalosporins are commonly used for 
the treatment of invasive Gram-negative bacterial infections in humans [52–54]. 
In 2017, there were an estimated 197,400 cases of ESBL Ent among hospitalized 
patients and 9100 estimated deaths in the US alone [55]. Among Enterobacteriaceae, 
Escherichia coli (E. coli) is the most common bacteria that reside in the gut as normal 
microflora or opportunist pathogen of animals and humans. However, certain 
pathogenic strains can cause diseases such as mastitis in cattle, neonatal calf diar-
rhea in calves and hemorrhagic enteritis, and more life-threatening conditions such 
as hemolytic uremic syndrome and urinary tract infections in humans. New strains 
of multi-drug resistant foodborne pathogens that produce extended-spectrum 
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beta-lactamases that inactivate nearly all beta-lactam antibiotics have been reported 
[30]. Ceftiofur is the most common 3GC used in dairy cattle operations [56]. The 
3GCs are also critically important antibiotics for the treatment of serious infections 
caused by Enterobacteriaceae such as Escherichia coli (E. coli) and Salmonella spp. in 
humans [57, 58]. The use of structurally and chemically similar antibiotics in dairy 
cattle production and human medicine may lead to co-resistance or cross-resistance 
[52–54]. Some of the species of Gram-negative environmental mastitis patho-
gens, such as E. coli, Klebsiella pneumoniae, Acinetobacter spp., Pseudomonas spp., 
Enterobacter spp. are the greatest threat to human health due to the emergence of 
strains that are resistant to all or most available antimicrobials [59, 60].
The resistance of Enterobacteriaceae to 3GC is mainly mediated by the produc-
tion of extended-spectrum beta-lactamase enzymes (ESBLs) that breakdown 3GC 
[61]. E. coli is one of the most frequently isolated Enterobacteriaceae carrying ESBL 
genes (blaCTX-M, blaSHV, blaTEM, and blaOXA) families [62–64]. These ESBL genes 
are usually carried on mobile plasmids along with other resistance genes such as 
tetracycline, quinolones, and aminoglycosides. E. coli resides in the gastrointestinal 
tract of cattle as normal or opportunistic microflora, but some strains (for e.g., 
0157:H7) cause serious infection in humans [58], indicating that cattle could serve 
as a reservoir of ESBLs producing E. coli (ESBLs E. coli) for human.
In the US, the occurrence of ESBLs E. coli in the dairy cattle was reported a 
decade ago from Ohio [52] and few previous studies reported the occurrence and 
an increase in the trend of ESBLs E. coli in the dairy cattle production system 
[52, 53, 65–67]. However, recent studies increasingly showed the rise of ESBLs 
E. coli in the cattle [51, 52, 65, 67]. Similarly, reports from the Center for Disease 
Control (CDC) showed a continuous increase in the number of community-asso-
ciated human infections caused by ESBLs-producing Enterobacteriaceae [55]. This 
CDC report showed a 9% average annual increase in the number of hospitalized 
patients from ESBLs pathogens in six consecutive years (from 2012 to 2017). As a 
result, the human health sector tends to blame dairy farms that routinely use the 
3GC for the rise of ESBLs pathogens such as E. coli [55, 68]. However, despite the 
general believe of possibility of transmission of antimicrobial-resistant bacteria 
from dairy farms to humans directly through contact or indirectly through 
food chain, there was no clear evidence-based data that showed the spread of 
antimicrobial-resistant bacteria from the dairy production system to humans. 
The opinion of the scientific community on the factors that drive the emergence 
and spread of antimicrobial-resistant bacteria also varies [69]. Transmission 
of an antimicrobial-resistant pathogen to humans could occur if contaminated 
unpasteurized milk and/or undercooked meat from culled dairy cows due to 
chronic mastitis is consumed [70]. So it is crucial to pasteurize milk or cook 
meat properly to reduce the risk of infection by antimicrobial-resistant bacteria 
[71]. It is not known, if pasteurization or proper cooking prevents the transfer of 
resistant genes from milk or meat to commensal or opportunistic bacteria in the 
human gastrointestinal tract (GIT), or the GIT of calves fed pasteurized waste 
milk. Mechanisms of antibiotic resistance gene transfer from resistant to suscep-
tible bacteria are not well known, and killing resistant pathogens alone may not 
be good enough to prevent the transfer of the resistance gene. Non-prudent use 
of antimicrobials in dairy farms increases selection pressure, which could result 
in the emergence, persistence, and horizontal transfer of antimicrobial-resistant 
determinants from resistant to non-resistant bacteria. Bacteria exchange resis-
tance genes through mobile genetic elements such as plasmids, bacteriophages, 
pathogenicity islands, and these genes may ultimately enter bacteria pathogenic 
to humans or commensal or opportunistic bacterial pathogens. The prudent use 
of antimicrobials in dairy farms requires identification of the pathogen causing 
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mastitis, determining the susceptibility/resistance of the pathogen, and proper 
dose, duration, and frequency of treatment to ensure effective concentrations of 
the antibiotic to eliminate the pathogen.
2.  Prospects for effective vaccines against major bacterial mastitis 
pathogens
Despite decades of research to develop effective vaccines against major bacterial 
bovine mastitis pathogens such as Staphylococcus aureus, Streptococcus uberis, and 
E. coli, the effective intramammary immune mechanism is still poorly understood, 
perpetuating reliance on antibiotic therapies to control mastitis in dairy cows. 
Dependence on antimicrobials is not sustainable because of their limited efficacy 
[46, 47] and increased risk of emergence of antimicrobial-resistant bacteria that 
pose serious public health threats [4, 72–74]. Neither of the two currently available 
commercial Bacterin vaccines against S. aureus (Table 1), Lysigin® (Boehringer 
Ingelheim Vetmedica, Inc., St. Joseph, MO) in the USA and Startvac® (Hipra, 
Girona, Spain) in Europe and other countries, confer protection from new intrama-
mmary infection under field trials as well as under controlled experimental chal-
lenge studies [75–81].
There are four commercial vaccines against E. coli mastitis which include 1) 
the Eviracor®J5 (Zoetis, Kalamazoo, MI), [82, 83], 2) Mastiguard®, 3) J-VAC® 
(Merial-Boehringer Ingelheim vet medical, Inc., Duluth, GA) and 4) ENDOVAC-
Bovi® (IMMVAC) (Endovac Animal Health, Columbia, MO) (Table 1). The 
Endovac-bovi® is a cross-protective vaccine made of genetically engineered 
R/17 mutant strain of Salmonella typhimurium and the core somatic antigen 
mutant J-5 strain of E. coli combined with an immune-potentiating adjuvant 
(IMMUNEPlus®). Endovac-bovi significantly reduces diseases caused by Gram-
negative bacteria producing various endotoxins and protects against E. coli mastitis 
and other endotoxin-mediated diseases caused by E. coli, Salmonella, Pasteurella 
multocida, and Mannheimia hemolytica. The UBAC® (Hipra, Amir, Spain) [84] is 
a recently developed vaccine against S. uberis mastitis with label claim of partial 
reduction in clinical severity of S. uberis mastitis.
Mastitis 
Pathogen
Vaccine Vaccine component Protective effect Reference
Commercial
S. aureus Lysigin® Bacterin: Somatic 
antigen containing 
phage types I, II, III, 
IV with different 
strains of S. aureus
Reduced SCC, clinical 
mastitis, and chronic 
IMI
[193–195]
“ “ Field-based studies 
concluded no such 
effect
[80, 81, 111, 
114, 196]
Startvac® Bacterin: E. coli J5 
and S. aureus CP type 
8 with SAAC
Decreased duration of 
IMI, transmissibility 
of S. aureus, coliforms, 
and CNS
[77]
“ “ Use of the vaccine was 
not associated with a 
decrease in mastitis
[75]
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Mastitis 
Pathogen
Vaccine Vaccine component Protective effect Reference
Bestvac® Vs Startvac herd-specific 
autologous vaccine 
compared with 
Startvac®
Both vaccines 
decreased herd 
prevalence of S. aureus 
mastitis but no other 
differences in terms of 
improvement of udder 
health
[78]
Experimental
Whole-cell lysate Bacterin 
encapsulated in 
biodegradable 
microspheres
Induced antibodies 
that were more opsonic 
for neutrophils and 
inhibited adhesion to 
mammary epithelium.
[115]
Whole-cell lysate 
from two strains
Bacterin from two 
strains (α and α + β 
hemolytic) plus 
supernatants from 
non-hemolytic strain
Vaccinated cows had 
70% protection from 
infection compared 
to less than 10% 
protection in control 
cows
[124]
MASTIVAC I Whole-cell lysate Improved udder health 
in addition to specific 
protection against S. 
aureus infection
[108]
Live pathogenic S. 
aureus through IM 
route
Live pathogenic S. 
aureus
Induce activation 
of immune cells in 
mammary gland and 
blood
[109]
Fibronectin 
binding protein and 
clumping factor A
DNA primed and 
protein boosted
Induced cellular and 
humoral immune 
responses that provide 
partial protection 
against S. aureus
[110]
Protein A of S. 
aureus with the green 
fluorescent protein
DNA Induced humoral 
and cellular immune 
responses
[197]
Plasmid encoding 
bacterial antigen 
β-gal
DNA Induced humoral 
and cellular immune 
responses
[117]
Polyvalent S. aureus 
Bacterin
Bacterin Eliminated some 
cases of chronic 
intramammary S. 
aureus infections
[111]
Lysigin® with 
three-isolates based 
experimental 
Bacterin
Bacterin Lysigin reduced the 
clinical severity and 
duration of clinical 
disease. None of the 
experimental Bacterins 
has significant effects
[80]
Polyvalent S. aureus 
Bacterin
Bacterin + antibiotic 
therapy
S. aureus 
intramammary 
infection cure rate 
increased
[114]
Whole-cell lysate Whole-cell trivalent 
vaccine containing 
CP types 5, 8 and 336 
with FIA or Alum 
adjuvants
Elicited antibody 
responses specific 
to the 3 capsular 
polysaccharides
[113]
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Mastitis 
Pathogen
Vaccine Vaccine component Protective effect Reference
CP conjugated 
to a protein and 
incorporated in 
polymicrospheres 
and emulsified in 
FIA
CP types 5, 8 and 336 Cows in both groups 
produced increased 
concentrations of 
IgG1, IgG2 antibodies, 
hyperimmune sera 
from immunized cows 
increased phagocytosis, 
decreased bacterial 
adherence to epithelial 
cells
[116]
Polysaccharide-
protein conjugates 
in FIA
Polysaccharide-
protein conjugate
SASP or SCSP Surface proteins Induced partial 
protection
[93]
Vaccination with Efb 
and LukM
Induced increased titers 
in serum and milk
[198]
Inactivated Bacterin Bacterin Partial protection [199]
S. uberis Commercial
UBAC® Extract from 
biofilm-forming 
strains of S. uberis
Reduce clinical signs, 
bacterial count, 
temperature, daily 
milk yield losses and 
increased the number 
of quarters with 
isolation and somatic 
cell count <200,000 
cells/mL of milk
[84]
Experimental
Killed S. uberis cells Bacterin Reduced numbers of 
homologous S. uberis 
in milk
[136]
Killed bacterial cells Bacterin of S. uberis 
and S. agalactiae
Parenteral vaccination 
has no effect on 
streptococcal mastitis
[200, 201]
Live S. uberis/ 
cutaneous route
Live S. uberis Some protective effect 
only on the homologous 
strain
[137]
GapC or chimeric 
CAMP factor
Protein Reduction in 
inflammation
[138]
PauA protein Partial protection [129]
Coliform Commercial
E. coli J5
Mastiguard®
J Vac®
Endovac-bovi® 
(IMMVAC)
Bacterin Reduce bacterial counts 
in milk, duration of IMI 
and resulted in fewer 
clinical symptoms
[82, 83, 
188–190]
SAAC: slime associated antigenic complex, SASP: Staphylococcus aureus surface proteins, SCSP: Staphylococcus 
chromogenes surface proteins, CP: Capsular polysaccharide, GapC: Glyceraldehyde-3-phosphate dehydrogenase C, 
pauA: plasminogen activator protein, FIA: Freund’s incomplete adjuvant, Efb: fibrinogen-binding protein, LukM: 
leukocidin subunit M.
Table 1. 
Commercialized and experimental vaccines against major bovine mastitis pathogens.
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2.1 Intramammary immune mechanisms
Intramammary immunity can be induced locally in the mammary gland or sys-
temically in the body and cross from the body into the mammary glands. Mammary 
gland pathogen that enters through teat opening interact with host innate defense 
system primarily with macrophages in the mammary gland. Macrophages recognize 
invading pathogens through its pattern recognition receptors (PRR) which binds 
to pathogen associated molecular patterns (PAMPs) and engulf and break down 
the foreign pathogen into small peptides and load on to MHC-II molecules move to 
the supramammary lymph nodes and display on its surface to the T cells. Naïve T 
cells bind with peptide on MHC-II molecule through its T- cell receptor and become 
activated and start secreting cytokines, which further stimulate B-cells to produce 
antibodies. Antibody produced by B-cells released into the blood circulation and 
depending on type of antibody may be released to the site of infection (e.g., IgG) 
and opsonize the infecting pathogen and subject them to destruction by opsono-
phagocytic mechanisms. Antibodies may also remain on mucosal surfaces (e.g., 
IgA) and bind to invading pathogens and prevent them from binding to host cells or 
tissue and thereby prevent colonization and infection.
Intramammary infection (IMI) leads to increased somatic cell count in the milk 
or mammary secretion. Somatic cells are mainly white blood cells such as granulo-
cytes (neutrophils, eosinophils, and basophils), monocytes or macrophages, and 
lymphocytes, which are recruited to the mammary glands in response to mammary 
gland infection to fight off infection. A small proportion of mammary epithelial 
cells that produce milk are also shed through milk and are included in the somatic 
cell count. So, somatic cells are white blood cells and mammary epithelial cells. 
Milk somatic cell count (SCC) increases when there is mammary gland infection 
(IMI) because of an inflammatory response to clear infection. In general, SCC is 
also an indicator of milk quality [85–89] because if there are few mammary patho-
genic bacteria in the gland, the inflammatory response is less, and somatic cells 
recruitment into the gland is also low and vice versa. Bulk tank milk (BTM) is milk 
collected from all lactating dairy cows in a farm into a tank or multiple tanks. So 
BTSCC is somatic cell counts obtained from milk sample collected from a tank.
Intramammary infection may progress to clinical or subclinical mastitis [90]. 
Clinically infected udder usually treated with antimicrobial, whereas subclini-
cally infected udder may not be diagnosed immediately and treated but remained 
infected and shedding bacteria through milk throughout lactation. The proportion 
of cure following treatment of mastitis varies and the variation in cure rate is multi-
factorial including cow factors (age or parity number, stage of lactation, and dura-
tion of infection, etc.), management factors (detection and diagnosis of infection 
and time from detection to treatment, availability of balanced nutrition, sanitation, 
etc.), factors related to antimicrobial use patterns (type, dose, route, frequency, and 
duration), and pathogen factors (type, species, number, pathogenicity or virulence, 
resistance to antimicrobial, etc.) [46, 91].
The dilution of effector humoral immune responses by large volume of milk 
coupled with the ability of mastitis causing bacteria to develop resistance to 
antimicrobials makes the control of mastitis very difficult. Therefore, the devel-
opment of an alternative preventive tool such as a vaccine, which can overcome 
these limitations, has been a crucial focus of current research to decrease not only 
the incidence of mastitis but also the use of antimicrobials in dairy cattle farms. 
Most vaccination strategies against mastitis have focused on the enhancement 
of humoral immunity. Development of vaccines that induce an effective cellular 
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immune response in the mammary gland has not been well investigated. The abil-
ity to induce cellular immunity, especially neutrophil activation and recruitment 
into the mammary gland, is one of the key strategies in the control of mastitis, but 
the magnitude and duration of increased cellular recruitment into the mammary 
gland leads to a high number of somatic cells and poor-quality milk. So, effective 
balanced humoral and cellular immunity that clear intramammary infection in a 
short period of time is required. Several vaccine studies were conducted over the 
years under controlled experimental and field trials. The major bacterial bovine 
mastitis pathogens that have been targeted for vaccine development are S. aureus, 
S. uberis, and E. coli [92]. Most of these experimental and some commercial 
vaccines are Bacterins which are inactivated whole organism, and some vac-
cines contained subunits of the organism such as surface proteins [93], toxins, or 
polysaccharides.
2.2 Vaccine trials against Staphylococcus aureus mastitis
Staphylococcus aureus is one of the most common contagious mastitis patho-
gens, with an estimated incidence rate ranging from 43–74% [25, 38, 56, 94, 95]. 
Staphylococcus chromogenes is another increasingly reported coagulase-negative 
Staphylococcus species with an estimated quarter incidence rate of 42.7% characterized 
by high somatic cell counts [96–102]. In a study on conventional and organic Canadian 
dairy farms, coagulase-negative Staphylococcus species were found in 20% of the 
clinical samples [103]. Recently, mastitis caused by coagulase-negative Staphylococcus 
species increasingly became more problematic in dairy herds [99, 101, 104, 105].
Several staphylococcal vaccine efficacy trials showed that vaccination with 
Bacterin vaccines induced increased antibody titers in the serum and milk that 
are associated with partial protection [75–77, 80, 106–112] or no protection at 
all [78, 79, 81]. However, effective intramammary immune mechanisms against 
staphylococcal mastitis is still poorly understood. None of the commercially 
available Bacterin vaccines protects new intramammary infection [75, 77, 80, 81]. 
Dependence on antibiotics for the prevention and treatment of mastitis is not 
sustainable because of limited success [46, 47] and the emergence of antimicrobial-
resistant bacteria that are major threat to human and animal health [72–74].
Despite several mastitis vaccine trials conducted against S. aureus mastitis 
[75, 77, 80, 107–111, 113–117], all field trials have either been unsuccessful or 
had limited success. There are two commercial vaccines for Staphylococcus aureus 
mastitis on the market, Lysigin® (Boehringer Ingelheim Vetmedica, Inc., St. 
Joseph, MO) in the United States and Startvac® (Hipra S.A, Girona, Spain) in 
Europe and Canada [78]. None of these vaccines confer protection under field 
trials as well as under controlled experimental studies [75, 77, 80, 81]. Several field 
trials and controlled experimental studies have been conducted testing the effi-
cacy of Lysigin® and Startvac®, and results from those studies have shown some 
interesting results, namely a reduced incidence, severity, and duration of mastitis 
in vaccinated cows compared to non-vaccinated control cows [75–77]. Contrary to 
these observations, other studies failed to find an effect on improving udder health 
or showed no difference between vaccinated and non-vaccinated control cows [78, 
79]. None of these Bacterin-based vaccines prevents new S. aureus IMI [75, 77, 80, 
81]. Differences found in these studies are mainly due to methodological differ-
ences (vaccination schedule, route of vaccination, challenge model, herd size, time 
of lactation, etc.) in testing the efficacy of these vaccines. It is critically important 
to have a good infection model that mimics natural infection and a model that has 
100% efficacy in causing infection. Without a good challenge model, the results 
from vaccine efficacy will be inaccurate.
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The Startvac® (Hipra, Girona, Spain) is the commercially available vaccine in 
Europe and is a polyvalent vaccine that contains E. coli J5 and S. aureus strain SP140 
[92]. In a field trial, Freick et al. [78] compared the efficacy of Startvac® with 
Bestvac® (IDT, Dessau-Rosslau, Germany) another herd-specific autologous com-
mercial vaccine in a dairy herd with a high prevalence of S. aureus and found that 
the herd prevalence of S. aureus mastitis was lower in the Startvac® and Bestvac® 
vaccinated cows compared to the control cows. However, there were no other differ-
ences in terms of improvement of udder health. These authors [78] concluded that 
vaccination with Startvac® and Bestvac® did not improve udder health. In another 
field efficacy study on Startvac® in the UK, Bradley et al. [75] found that Startvac® 
vaccinated cows had clinical mastitis with reduced severity and higher milk produc-
tion compared to non-vaccinated control cows [75].
Similarly, Schukken et al. [77] evaluated effect of Startvac® on the develop-
ment of new IMI and the duration of infections caused by S. aureus and CNS. These 
authors [77] found that vaccinated cows had decreased incidence rate and a shorter 
duration of S. aureus and CNS mastitis. Piepers et al. [76], also tested the efficacy 
of Startvac® through vaccination and subsequent challenge with a heterologous 
killed S. aureus strain and found that the inflammatory response in the vaccinated 
cows was less severe compared to the control cows. These authors [76] suggested 
that Startvac® elicited a strong Th2 immune response against S. aureus in vac-
cinated cows and was more effective at clearing bacteria compared to the control 
cows. Contrary to these observations, Landin et al. [118], evaluated the effects of 
Startvac® on milk production, udder health, and survival on two Swedish dairy 
herds with S. aureus mastitis problems and found no significant differences between 
the Startvac® vaccinated and non-vaccinated control cows on the health param-
eters they evaluated.
An experimental S. aureus vaccine made up of a combination of plasmids 
encoding fibronectin-binding motifs of fibronectin-binding protein (FnBP) and 
clumping factor A (ClfA), and plasmid encoding bovine granulocyte-macrophage-
colony stimulatory factor, was used as a vaccine with a subsequent challenge with 
bacteria to test its protective effects [110]. These authors (Shkreta et al. 2004) 
found that their experimental vaccine-induced immune responses in the heifers 
that were partially protective upon experimental challenge [110]. Another con-
trolled experimental vaccine efficacy study was conducted on the slime associated 
antigenic complex (SAAC) which is an extracellular component of Staphylococcus 
aureus, as vaccine antigen in which one group of cows were vaccinated with a 
vaccine containing a low amount of SAAC and another group with a high amount 
of SAAC and the unvaccinated group served as a control [119]. Upon intramam-
mary infusion (challenge) with S. aureus, no difference in the occurrence of 
mastitis among all three groups despite the fact that the vaccine with high SAAC 
content induced higher production of antibodies compared to the vaccine with a 
low amount of SAAC [119]. Similarly, Pellegrino et al. [120], vaccinated dairy cows 
with an avirulent mutant strain of S. aureus and subsequently challenged with S. 
aureus 20 days after the second vaccination which resulted in no significant differ-
ences in the number of somatic cell count (SCC) or number of bacteria shedding 
through milk despite increased IgG antibody titer in the vaccinated cows compared 
to the control cows.
Some of the constraints affecting the successful development of effective mastitis 
vaccines are strain variation, the presence of exopolysaccharide (capsule, slime, 
biofilm) layer in most pathogenic strains of bacteria (Staph. aureus, Strep. uberis) 
which does not allow recognition of antibody-coated bacteria by phagocytic cells, 
dilution of immune effectors by milk [121, 122], the interaction between milk com-
ponents and immune effectors [123] that reduce their effectiveness, and the ability 
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of most mastitis-causing bacteria to attach and internalize into mammary epithelial 
cells. Furthermore, evaluation of mastitis vaccines is complicated by the absence of 
uniform challenge study models, and lack of uniform route(s) of vaccination, time 
of vaccination, adjuvants, and challenge dose. There is an increasing need for devel-
opment of better vaccines that overcome these problems. Most mastitis vaccines are 
killed whole bacterial cells (Bacterin) vaccines [75, 77, 80, 108–111, 113–117, 124] that 
are difficult to improve because of difficulty to specifically identify an immunogenic 
component that induced partial or some protective effect. In this regard, some of the 
current efforts to use a mixture of purified surface proteins as vaccine antigens [93] 
to induce immunity than killed whole bacterial cells (Bacterin) is encouraging. A 
better understanding of natural and acquired immunological defenses of the mam-
mary gland coupled with detailed knowledge of the pathogenesis of each mammary 
pathogen should lead to the development of improved methods of reducing the 
incidence of mastitis in dairy cows.
2.3 Vaccine trials against Streptococcus uberis
S. uberis is ubiquitous in the cow’s environment accounting for a significant 
number of mastitis cases. It is found on-farm in water, soil, plant material, 
bedding, flies, hay, and feces [125]. As such, S. uberis is remarkably adaptable, 
affecting lactating and dry cows, heifers, and multiparous cows, causing clinical 
or subclinical mastitis, and even being responsible for persistent colonization 
without an elevation in the somatic cell count [126, 127]. It has been described 
as an environmental pathogen [128–131] with potential as a contagious pathogen 
[126, 127, 132]. S. uberis has ability to persist within the mammary gland which 
lead to chronic mastitis that is difficult to treat [133]. Coliform bacteria are a major 
cause of clinical mastitis [134, 135]. A vaccine that prevents S. uberis mastitis is not 
available, control measures are limited to the implementation of good manage-
ment practices. Recently vaccine efficacy trial with extract of biofilm-forming 
strains of S. uberis (UBAC®) (Hipra, Amir, Spain), was reported to reduce clinical 
severity [84]. It is not clear what kind of adative immunity is induced by UBAC® 
S. uberis vaccine [84] and it only conferred partial reduction in clinical severity of 
mastitis. Multiple intramammary vaccinations of dairy cows with killed S. uberis 
cells resulted in the complete protection from experimental infection with the 
homologous strain [136]. Similarly, subcutaneous vaccination of dairy cows with 
live S. uberis followed by intramammary booster vaccination with S. uberis cell 
surface extract protected against challenge with the homologous strain but was less 
effective against a heterologous strain [137]. Vaccination with S. uberis glyceralde-
hyde phosphate dehydrogenase C (GapC) protein induced immune responses that 
confer a significant reduction in inflammation post-challenge [138, 139]. The pauA 
is a plasminogen activator and also binds active protease plasmin [140]. It has been 
postulated that acquisition of plasmin may promote invasion [141]. Vaccination of 
dairy cows with PauA induced increased antibody titers that conferred reduction 
in clinical severity [142]. However, mutation of pauA did not alter ability to grow 
in milk or to infect lactating bovine mammary glands. It appears that the ability to 
activate plasminogen through PauA does not play a major role in pathogenesis of S. 
uberis to either grow in milk or infect bovine mammary gland [143].
S. uberis expresses several surface associated proteins such as S. uberis adhe-
sion molecule (SUAM) and extracellular matrix binding proteins, which allow it 
to adhere to and internalize into mammary epithelial cells, successfully inducing 
IMI [144–146]. The S. uberis adhesion molecule (SUAM) plays a central role in 
the adherence of S. uberis to mammary epithelial cells [147–150]. Vaccination 
of dairy cows with SUAM induced strong immune resposes in vaccinated cows 
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[151]. The immune serum from SUAM vaccinated cows prevented S. uberis adhe-
sion and invasion into mammary epithelial cells in vitro [151]. In vivo infusion 
of mammary quarters of dairy cows with S. uberis pre-incubated with immune-
serum from SUAM vaccinated cows reduced clinical severity [152]. The SUAM 
gene deletion mutant strain is less pathogenic to mammary epithelial cells [153] 
and to dairy cows [147]. Controlled experimental efficacy studies using SUAM as 
vaccine antigen to control S. uberis mastitis showed that SUAM is immunogenic 
but the induced immunity was not protective. Following experimental IMI chal-
lenge with S. uberis, clinical signs emerged at about 48 h, along with increased 
levels of inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8 in milk 
at 60 h post-infection [154]. Adaptive immune response cytokines such as IFN-γ 
promotes a cell-mediated immune response by enhancing functions such as 
macrophage bacterial killing, antigen presentation, cytotoxic T cell activation, 
and increased IgG2 levels. The IL-4 expression is associated with the antibody-
mediated response, which is generally linked to parasite resistance, allergic reac-
tions, and increased levels of IgG1 [155, 156]. This partial protection by the SUSP 
vaccine can be improved with dose optimization, appropriate adjuvant, route of 
injection, and timing of vaccination.
In conclusion, it is clear that Bacterin vaccines have some protective effect 
against homologous strains, and single surface protein is not effective. Therefore; 
use of multiple surface proteins may induce better immunity that prevents clinical 
disease and production losses.
2.4 Vaccine trials against E. coli mastitis
Coliform bacteria are a major cause of clinical mastitis [134, 135]. Coliforms 
include the genera Escherichia, Klebsiella, and Enterobacter [157]. Eighty to ninety 
percent of coliform intramammary infection (IMI) develop clinical mastitis, and 
10% will be severe and could lead to death [135]. E. coli usually infects the mam-
mary glands during the dry period and progresses to inflammation and clinical 
mastitis during the early lactation with local and sometimes severe systemic clinical 
manifestations.
Iron is an essential nutrient for the growth of coliforms [158]. However, free 
iron is limited in the bovine milk because most iron is bound to citrate and to a 
lesser extent to lactoferrin, transferrin, xanthine oxidase, and some caseins [159] 
and maintained at concentrations below levels required to support coliform growth 
[160]. To overcome this limited iron source, coliforms express multiple iron trans-
port systems [161], which include synthesis of siderophores (e.g., enterobactin, 
aerobactin, ferrichrome) that bind iron with high affinity [162], the expression of 
iron-regulated outer membrane proteins (IROMP) that binds to ferric siderophore 
complexes to transport into bacterial cell and enzymes to utlize the chelated iron 
[161]. The siderophores are too large (600 to 1200 Da) to pass through the porin 
channels of the bacterial outer membrane [163, 164]. Therefore, the siderophores 
require specific IROMP to enable their passage across the bacterial outer membrane 
into the periplasm [165, 166]. The enterobactin is a siderophore with the highest 
affinity for iron, and it is produced by most pathogenic E. coli and Klebsiella spp. 
[167–169]. The aerobactin is another siderophore that was detected in only 12% of 
E. coli isolated from mastitis cases [170]. Enterobactin is the primary siderophore 
of Escherichia coli and many other Gram-negative bacteria [171]. Coliform bacteria 
also developed the ability to take up iron directly from naturally occurring organic 
iron-binding acids, including citrate [161, 172]. The citrate iron uptake system 
requires ferric dicitrate for induction [172]. More than 0.1 mM citrate is required 
for the induction of this system under iron-restricted conditions [172]. The ferric 
Animal Reproduction in Veterinary Medicine
14
citrate transport system is the major iron acquisition system utilized by E. coli [161] 
to grow in the mammary gland. The mammary gland is an iron-restricted environ-
ment, and bovine milk contains approximately 7 mM citrate [173] which is ideal for 
induction of ferric citrate transport sytem.
Ferric enterobactin receptor, FepA, is an 81 kDa iron regulated outer membrane 
protein (IROMP), that binds to ferric enterobactin complex to transoport iron 
into the bacterial cell [174, 175]. Vaccination of dairy cows with FepA elicited an 
increased immunological response in serum and milk [176]. Bovine IgG directed 
against FepA inhibited the growth of coliform bacteria by interfering with the 
binding of the ferric enterobactin complex [177]. Ferric citrate receptor, FecA, is 
an 80.5-kDa IROMP that is responsible for the binding of ferric dicitrate [178] and 
transport into the bacterial cell. The FecA, is conserved among coliforms isolated 
from cases of naturally occurring mastitis [179]. The iron-regulated outer mem-
brane proteins, FepA and FecA are ideal vaccine candidates because they are surface 
exposed, antigenic, and conserved among isolates from IMI.
Immunization of dairy cows with FepA induced significantly higher serum 
and whey anti-FepA IgG titers than in E. coli J5 vaccinates [176]. Results of in vitro 
growth inhibition studies demonstrated that antibody specific for blocking fer-
ric enterobactin-binding site (anti-FepA) inhibited the growth of E. coli in vitro 
[180]. Cows immunized with FecA did have increased antibody titers in serum and 
mammary secretions compared with E. coli J5 immunization and unimmunized 
control cows [181, 182]. Antibody purified from colostrum inhibited the growth of 
E. coli when cultured in synthetic media modified to induce FecA expression [181]. 
Despite their antigenicity, the use of either FepA or FecA alone were not sufficient 
to prevent mastitis. The FecA and FepA are antigenically distinct [179].
Intramammary infection with E. coli induced expression and release of pro-
inflammatory cytokines such as TNF-alpha, IL-8, IL-6, and IL-1 [183, 184]. 
Recently it has been shown with mouse mastitis models that IL-17A and Th17 cells 
are instrumental in the defense against E. coli IMI [185, 186]. However, the role 
of IL-17 in bovine E. coli mastitis is not well defined. Results of a recent vaccine 
efficacy study against E. coli mastitis suggested that cell-mediated immune response 
has more protective effect than humoral response [187]. The cytokine signaling 
pathways that lead to efficient bacterial clearance is not clearly defined.
The four coliform vaccines which include 1) J-5 Bacterin® (Zoetis, Kalamazoo, 
MI) [82, 83], 2) Mastiguard®, 3) J Vac® (Merial-Boehringer Ingelheim vet medi-
cal, Inc., Duluth, GA) and 4) Endovac-bovi® (IMMVAC) (Endovac Animal Health, 
Columbia, MO). Of the four coliform vaccines, J-5 Bacterin® and Mastiguard® are 
believed to have the same component, which is J5 Bacterin. The J Vac® is a differ-
ent bacterin-toxoid. The Endovac-Bovi® contains mutant Salmonella typhimurium 
bacterin toxoid. All coliform mastitis vaccine formulations use gram-negative core 
antigens to produce non-specific immunity directed against endotoxin (LPS) [92]. 
The efficacy of these vaccines has been demonstrated in both experimental chal-
lenge trials and field trials in commercial dairy herds [188–190]. The principle of 
these bacterins is based upon their ability to stimulate the production of antibodies 
directed against common core antigens that gram-negative bacteria share. These 
vaccines are considered efficacious even though the rate of intramammary infec-
tion is not significantly reduced in vaccinated animals because they significantly 
reduce the clinical effects of the infection. Experimental challenge studies have 
demonstrated that J5 vaccines are able to reduce bacterial counts in milk and result 
in fewer clinical symptoms [188]. Vaccinated cows may become infected with gram-
negative mastitis pathogens at the same rate as control animals but have a lower 
rate of development of clinical mastitis [190], reduced the duration of IMI [189], 
reduced production, culling, and death losses [191, 192].
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There is an increasing need for the development of effective vaccines against 
major bacterial bovine mastitis pathogens. A better understanding of the natural and 
acquired immunological defenses of the mammary gland coupled with detailed knowl-
edge of the pathogenesis of each mammary pathogen should lead to the development 
of improved methods of reducing the incidence of mastitis in dairy cows (Table 1).
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